Form 4: Crinetics Pharmaceuticals Director Caren Deardorf Reports Acquisition of Restricted Stock Units and Stock Options

Director Caren Deardorf reports acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals, Inc.

Summary

• Caren Deardorf, a director of Crinetics Pharmaceuticals, Inc., reported changes in beneficial ownership on June 11, 2024.
• On June 7, 2024, Deardorf acquired 3,400 shares of common stock through restricted stock units at a price of $0.
• Deardorf also acquired stock options for 12,500 shares of common stock at an exercise price of $44.71, expiring on June 7, 2034.
• Following these transactions, Deardorf directly owns 9,400 shares of common stock and holds options for 12,500 shares.
• The restricted stock units vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continued service on the board.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director increasing their stake in the company, which can be interpreted as a sign of confidence. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of restricted stock units and stock options by a director signals confidence in the company's future performance.
• The vesting conditions tied to continued service on the board align the director's interests with those of the shareholders.

Future Outlook

The vesting of the restricted stock units and stock options is contingent on the director's continued service on the board, aligning their interests with the company's long-term success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their company's stock. This allows investors to monitor insider activity, which can provide insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.
• The vesting conditions tied to continued service align the director's interests with those of the shareholders.

Key Dates